Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel (cas 113665-84-2) Response in Patients Subjected to a Percutaneous Neurointervention
-
Add time:08/25/2019 Source:sciencedirect.com
PurposeClopidogrel (cas 113665-84-2) is a thienopyridine prodrug that inhibits platelet aggregation. It is prescribed to prevent atherothrombotic and thromboembolic events in patients receiving a stent implant in carotid, vertebral, or cranial arteries. The influence of cytochrome P-450 (CYP) 2C19 on the response to clopidogrel has been widely studied; however, the effect of other genes involved in clopidogrel absorption and metabolism has not been established in this cohort of patients.
We also recommend Trading Suppliers and Manufacturers of Clopidogrel (cas 113665-84-2). Pls Click Website Link as below: cas 113665-84-2 suppliers
Prev:Original¿Cuál es la dosis óptima de Clopidogrel (cas 113665-84-2) en pacientes pediátricos?What is the optimal dose of Clopidogrel (cas 113665-84-2) in pediatric patients?
Next:Efficacy and safety of Clopidogrel (cas 113665-84-2) only vs. Clopidogrel (cas 113665-84-2) added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ArticleCarotid Endarterectomy and Concurrent Clopidogrel (cas 113665-84-2) Use: National Practice Patterns in the United States08/29/2019
- Clopidogrel (cas 113665-84-2)☆08/28/2019
- Silver nanoparticles impregnated chitosan layered carbon nanotube as sensor interface for electrochemical detection of Clopidogrel (cas 113665-84-2) in-vitro08/27/2019
- Efficacy and safety of Clopidogrel (cas 113665-84-2) only vs. Clopidogrel (cas 113665-84-2) added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis08/26/2019
- Original¿Cuál es la dosis óptima de Clopidogrel (cas 113665-84-2) en pacientes pediátricos?What is the optimal dose of Clopidogrel (cas 113665-84-2) in pediatric patients?08/24/2019
- Influence of statin treatment on pharmacokinetics and pharmacodynamics of Clopidogrel (cas 113665-84-2) and its metabolites in patients after coronary angiography/angioplasty08/23/2019
- OriginalConsecuencias clínicas y económicas en pacientes que inician tratamiento con Clopidogrel (cas 113665-84-2) de marca vs. genérico: estudio retrospectivo de vida realClinical and economic consequences in patients initiating therapy with Clopidogrel (cas 113665-84-2) brand-name vs. generic: A real-life retrospective study08/22/2019
- Original ArticleWhat is the optimal dose of Clopidogrel (cas 113665-84-2) in paediatric patients?¿Cuál es la dosis óptima de Clopidogrel (cas 113665-84-2) en pacientes pediátricos?☆08/21/2019
-
Health and Chemical more >